A drug used to prevent excessive bleeding during bypass surgery should remain on the market despite being linked to increased risk of death and other serious side effects, federal advisers recommended Wednesday.
The drug is aprotinin, sold by Bayer AG under the brand name Trasylol. The Food and Drug Administration approved it in 1993 to stanch the loss of blood and prevent the need for blood transfusions in surgeries to bypass clogged coronary arteries.
Las Vegas Sun September 12, 2007